Recent

% | $
Quotes you view appear here for quick access.

SciClone Pharmaceuticals, Inc. Message Board

stev_26_2000 2 posts  |  Last Activity: Mar 31, 2016 6:27 PM Member since: Jan 16, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Starting to see some articles posted on Pubmed regarding a certain fragment of TB4: Check it out. "Preventive and therapeutic effects of Thymosin β4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosis." This was published by the Italians and there is another one by Henry Ford.

    Steve

  • Reply to

    Tivantinib

    by gizmo_puppy95 Mar 19, 2016 7:45 PM
    stev_26_2000 stev_26_2000 Mar 20, 2016 4:51 PM Flag

    Pfizer did not buy 4+ million shares. This filing just updates their percentage holdings to 4.4%. Due to the dilution their holdings dropped below the 5% threshold. Looks like Pfizer still holds their shares of ARQL they obtained back in the days when ARQL was also a chemical company.

    (2)Amount consists of 3,273,679 shares of the Issuer’s Common Stock held by Pfizer Holdings Europe. As a wholly owned subsidiary of Pfizer Inc., Pfizer Holdings Europe shares the power to vote and dispose of the shares with Pfizer Inc.

    This Amendment No. 4 (this “Amendment No. 4”) amends and supplements the statement on Schedule 13D originally filed by Pfizer Inc. (“Pfizer”) and Pfizer Holdings Europe (“PHE” and, together with Pfizer, the “Reporting Persons”) with the U.S. Securities and Exchange Commission on March 24, 2003 (the “Original Schedule 13D”), as amended by Amendment No. 1 to the Schedule 13D, filed on December 22, 2003 (“Amendment No. 1”), Amendment No. 2 to the Schedule 13D, filed on February 14, 2006 (“Amendment No. 2”) and Amendment No. 3 to the Schedule 13D, filed on May 1, 2015 (“Amendment No. 3” and, with the Original Schedule 13D, Amendment No. 1 and Amendment No. 2, the “Schedule 13D”) and relates to the common stock, par value $0.01 per share (“Common Stock”), of ArQule, Inc. (the “Issuer”). This Amendment No. 4 is being filed to update the percentage of Common Stock of the Issuer beneficially owned by Pfizer and PHE as a result of dilution due to equity issuances by the Issuer. Except as specifically provided herein, this Amendment No. 4 does not modify any of the information previously reported on the Schedule 13D. Unless otherwise indicated, each capitalized term used but not defined herein shall have the meaning assigned to such term in the Schedule 13D.

SCLN
13.125+0.095(+0.73%)May 27 4:00 PMEDT